Chronic heart failure can occur when the structure and function of our heart are abnormal for various reasons, resulting in impaired ejection or filling capacity of the ventricles. At this time, the function of the heart, which is the “power pump” of the whole body blood circulation, will be weakened or lost, and it will neither be able to squeeze fresh blood to all organs of the body, nor have enough space to absorb the returning blood, so the patient will have various symptoms such as weakness, difficulty in breathing, and fluid retention. In the treatment of heart failure, the rational selection of drugs is a very important aspect. Chronic heart failure is a process that worsens over time, and taking medications can help slow and halt its progression. Scholars have graded heart failure according to its different stages of progression, and each grade has its own recommended therapeutic drugs. It should be noted that, in general, patients can only progress gradually and cannot return to the next level, i.e., from B, C or even D to A. Therefore, it is particularly important for patients with heart failure to slow down the progression of the disease through medication. The following is a description of the characteristics of each class and the appropriate medications for each class. class A mainly corresponds to people at high risk of chronic heart failure, such as hypertension, diabetes, coronary artery disease, history of medication that may lead to chronic heart failure, alcoholism, familial cardiomyopathy, etc. Treatment: regular exercise, smoking cessation, treatment of hypertension, treatment of hyperlipidemia, alcohol cessation and elimination of substance abuse. Patients with previous heart attack, hypertension, diabetes mellitus apply ACEI class of drugs, previous heart attack may also apply beta-blockers. class B diagnosis of systolic chronic heart failure without symptoms. There are structural and functional abnormalities of the heart. Treatment: Apply class A therapy, while all patients should receive ACEI and beta-blocker therapy. The physician and patient should discuss the choice of treatment with cause for removal, such as hemodynamic reconstruction and correction of valve function. class C has structural and functional heart abnormalities and is symptomatic. Treatment: Class A therapy is applied and all patients should receive ACEI and beta-blocker therapy. Diuretics and digoxin may be applied, salt intake is restricted, weight is monitored, and fluid intake is appropriately limited. Drugs that worsen cardiac function should be discontinued. If the patient is still symptomatic after the above treatment spironolactone should be added to the treatment. grade D, despite the application of the best treatment, often requires special treatment due to significant structural changes in the heart and prominent patient symptoms, corresponding to the end state. Treatment: Application of A, B and C treatment. At this point, in addition to drug therapy, the patient should be evaluated for the following methods of treatment: left heart assist device, heart transplantation, cardiac resynchronization therapy, etc. Continuous titration of positive inotropic drugs and end-of-life care. A concept needs to be introduced here – standardized treatment of chronic heart failure, which precisely refers to effective therapeutic drugs that have been proven in meticulously designed large clinical trials to have the potential to reduce the risk of worsening chronic heart failure and to improve symptoms and prognosis, and currently include: ACEI (angiotensin-converting enzyme inhibitor), ARB (angiotensin II1 receptor receptor blockers), some β-adrenergic receptor blockers and aldosterone receptor blockers. Among them, ACEI, ARB, β-blocker and spironolactone therapy contribute to the stabilization of chronic heart failure and improve prognosis and quality of life. Evidence-based medicine affirms the dominant role of these agents in the treatment of chronic heart failure. Other agents only contribute to symptomatic improvement, have no prognostic impact, and are adjuncts to chronic heart failure treatment, such as digoxin, some diuretics, and vasodilators. Some non-digoxigenin positive inotropic drugs, on the other hand, have a negative prognostic impact and are only used for a short period of time when chronic heart failure requires stabilization, and intravenous positive inotropic drug dependence is often end-state or for those awaiting transplantation.